Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URT035
MIFTS: 35

Urethral Benign Neoplasm

Categories: Cancer diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Urethral Benign Neoplasm

About this section

MalaCards integrated aliases for Urethral Benign Neoplasm:

Name: Urethral Benign Neoplasm 12
Urethral Neoplasms 44 73
Urethra Cancer 12 15
Malignant Neoplasm of Urethra 73
Malignant Tumour of Urethra 12
Malignant Urethral Neoplasm 12
Neoplasm of Urethra 12
Urethral Carcinoma 73
Neoplasm. Urethra 12
Cancer of Urethra 12
Urethral Ca 12

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:730 DOID:734
MeSH 44 D014523
ICD10 33 C68.0
ICD9CM 35 189.3
Sources

Summaries for Urethral Benign Neoplasm

About this section
Disease Ontology : 12 An urinary tract cancer that derives from the tissues of the urethra.

MalaCards based summary : Urethral Benign Neoplasm, also known as urethral neoplasms, is related to urethra adenocarcinoma and posterior urethra cancer. An important gene associated with Urethral Benign Neoplasm is FNDC3B (Fibronectin Type III Domain Containing 3B), and among its related pathways/superpathways is Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex. The drugs Gemcitabine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and endothelial, and related phenotype is homeostasis/metabolism.

Sources

Related Diseases for Urethral Benign Neoplasm

About this section

Diseases in the Urethral Cancer family:

Urethral Benign Neoplasm

Diseases related to Urethral Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
# Related Disease Score Top Affiliating Genes
1 urethra adenocarcinoma 25.7 ALK AMACR ANKRD28 APP ARID2 ATM
2 posterior urethra cancer 12.0
3 anterior urethra cancer 12.0
4 urethra transitional cell carcinoma 10.9
5 urethral cancer 10.9
6 urethra squamous cell carcinoma 10.9
7 radiation cystitis 10.5 KLK3 UPK3A
8 prostate signet ring cell adenocarcinoma 10.4 CEACAM5 KLK3
9 prostatic acinar adenocarcinoma 10.4 AMACR KLK3
10 nodular ganglioneuroblastoma 10.4 ALK CHGA
11 nephrogenic adenoma 10.4 AMACR KLK3
12 endodermal sinus tumor 10.4 CHGA KLK3
13 vulval paget's disease 10.4 CEACAM5 UPK3A
14 rete testis adenocarcinoma 10.4 CEACAM5 KLK3
15 vulva adenocarcinoma 10.3 CEACAM5 UPK3A
16 atypical follicular adenoma 10.3 CEACAM5 CHGA
17 pancreatic serous cystadenoma 10.3 CEACAM5 CHGA
18 rete testis neoplasm 10.3 CEACAM5 KLK3
19 acute thyroiditis 10.3 CEACAM5 CHGA
20 prostate squamous cell carcinoma 10.3 CEACAM5 KLK3
21 bladder disease 10.3 KLK3 UPK3A
22 liver sarcoma 10.3 CEACAM5 CHGA
23 acinar cell carcinoma 10.3 CHGA SMAD4
24 gastric small cell carcinoma 10.2 CEACAM5 CHGA
25 telangiectasis 10.2 ATM SMAD4
26 pancreatic cystadenocarcinoma 10.2 CEACAM5 CHGA
27 parotid gland cancer 10.2 ALK SMAD4
28 urethral diverticulum 10.1 AMACR KLK3 UPK3A
29 binswanger's disease 10.0 APP CHGA
30 clear cell adenocarcinoma 10.0 AMACR KLK3 SMAD4
31 female urethral cancer 10.0 CEACAM5 CHGA KLK3
32 male reproductive organ cancer 10.0 AMACR CHGA KLK3
33 mixed ductal-endocrine carcinoma 9.9 CEACAM5 CHGA SMAD4
34 descending colon cancer 9.9 APP CEACAM5
35 female breast cancer 9.9 ATM KLK3
36 endocrine gland cancer 9.9 CEACAM5 CHGA SMAD4
37 urethritis 9.7
38 prostatitis 9.7
39 prostatic adenoma 9.7
40 adenoma 9.7
41 suppression of tumorigenicity 12 9.6 AMACR CHGA KLK3 SMAD4
42 cell type cancer 9.5 ALK CEACAM5 CHGA KLK3
43 lung cancer susceptibility 3 9.4 ALK CEACAM5 SMAD4
44 gastric adenocarcinoma 9.1 CEACAM5 CHGA SMAD4
45 urethra clear cell adenocarcinoma 6.3 ALK AMACR ANKRD28 APP ARID2 ATM

Comorbidity relations with Urethral Benign Neoplasm via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Cancer
Hydronephrosis Prostate Cancer
Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Urethral Benign Neoplasm:



Diseases related to Urethral Benign Neoplasm
Sources

Symptoms & Phenotypes for Urethral Benign Neoplasm

About this section

MGI Mouse Phenotypes related to Urethral Benign Neoplasm:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.28 AMACR APP ARID2 ATM CHGA FNDC3B
Sources

Drugs & Therapeutics for Urethral Benign Neoplasm

About this section

Drugs for Urethral Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
6
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
7
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
8
Bevacizumab Approved, Investigational Phase 3 216974-75-3
9
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
11
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
12 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
13 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
14 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
15 Anti-Infective Agents Phase 3,Phase 2,Phase 1
16 Antimetabolites Phase 3,Phase 2,Phase 1
17 Antiviral Agents Phase 3,Phase 2,Phase 1
18 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
19 Folic Acid Antagonists Phase 3,Phase 2
20 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
21 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
22 Dermatologic Agents Phase 3,Phase 2
23 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
24 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
25 Vitamin B Complex Phase 3,Phase 2,Phase 1
26 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
27 Antirheumatic Agents Phase 3,Phase 2
28 Antimitotic Agents Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
30 Antibodies Phase 3,Phase 2,Phase 1
31 Immunoglobulins Phase 3,Phase 2,Phase 1
32 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
33 Mitogens Phase 3
34 Endothelial Growth Factors Phase 3
35 Immunoglobulin G Phase 3
36 Folate Nutraceutical Phase 3,Phase 2,Phase 1
37 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
38
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
39
Fluorouracil Approved Phase 2 51-21-8 3385
40
Lenograstim Approved, Investigational Phase 2 135968-09-1
41
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
42
Ifosfamide Approved Phase 2 3778-73-2 3690
43
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
44
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
45
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
46
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
47
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
48
Trastuzumab Approved, Investigational Phase 2,Phase 1 180288-69-1 9903
49
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
50
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
2 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
3 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
4 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
5 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
6 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
7 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Unknown status NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
8 Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer Unknown status NCT01118039 Phase 2 sunitinib malate
9 Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract Unknown status NCT00006111 Phase 2 cisplatin;fluorouracil
10 Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium Unknown status NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
11 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
12 TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium Completed NCT00077688 Phase 2 TOCOSOL Paclitaxel
13 S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium Completed NCT00055835 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride;paclitaxel
14 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
15 Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment Completed NCT01031875 Phase 2 pazopanib hydrochloride
16 Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium Completed NCT01090466 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;temsirolimus
17 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2 piritrexim
18 Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium Completed NCT00080795 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;ifosfamide
19 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2 rubitecan
20 Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer Completed NCT00004223 Phase 2 docetaxel;gemcitabine hydrochloride
21 Arsenic Trioxide in Treating Patients With Urothelial Cancer Completed NCT00009867 Phase 2 arsenic trioxide
22 Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00053209 Phase 2 gemcitabine hydrochloride;pemetrexed disodium
23 S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium Completed NCT00045630 Phase 2 carboplatin;gemcitabine;paclitaxel
24 SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00006351 Phase 2 gemcitabine hydrochloride;lonafarnib
25 Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function Completed NCT00005644 Phase 2 gemcitabine hydrochloride;paclitaxel
26 Pazopanib in Treating Patients With Metastatic Urothelial Cancer Completed NCT00471536 Phase 2 pazopanib hydrochloride
27 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium Completed NCT00397488 Phase 2 sunitinib malate
28 Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer Completed NCT00003175 Phase 2 fluorouracil
29 S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00014144 Phase 2 gefitinib
30 S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy Completed NCT00066612 Phase 2 irinotecan hydrochloride
31 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Completed NCT00661609 Phase 2 AZD4877
32 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function Completed NCT00478361 Phase 2 Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim
33 Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00072150 Phase 2 bortezomib
34 Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer Completed NCT00021099 Phase 2 ixabepilone
35 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
36 LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer Recruiting NCT02612194 Phase 2 Crizotinib
37 A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Recruiting NCT03219333 Phase 2 Enfortumab vedotin
38 Afatinib in Advanced Refractory Urothelial Cancer Recruiting NCT02122172 Phase 2 afatinib dimaleate
39 Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Recruiting NCT03237780 Phase 2 Atezolizumab;Eribulin Mesylate
40 Cabozantinib for Advanced Urothelial Cancer Active, not recruiting NCT01688999 Phase 2 Cabozantinib
41 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting NCT00082706 Phase 2 5-Fluorouracil (5-FU);Leucovorin;Cisplatin;Gemcitabine
42 Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Active, not recruiting NCT02178241 Phase 2 Eribulin Mesylate;Gemcitabine Hydrochloride
43 A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function Active, not recruiting NCT02665039 Phase 2 Vinflunine;Gemcitabine;Carboplatin
44 Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Not yet recruiting NCT03513952 Phase 2 Atezolizumab
45 Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer Terminated NCT01611662 Phase 2 gemcitabine hydrochloride;cisplatin
46 S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
47 S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium Terminated NCT00087295 Phase 2 Depsipeptide
48 Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium Terminated NCT00004856 Phase 2
49 Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Terminated NCT00112905 Phase 2 sorafenib tosylate
50 Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer Withdrawn NCT01639521 Phase 2 cisplatin;gemcitabine hydrochloride;methotrexate;vinblastine;doxorubicin hydrochloride

Search NIH Clinical Center for Urethral Benign Neoplasm

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: urethral neoplasms

Sources

Genetic Tests for Urethral Benign Neoplasm

About this section
Sources

Anatomical Context for Urethral Benign Neoplasm

About this section

MalaCards organs/tissues related to Urethral Benign Neoplasm:

41
Kidney, Prostate, Endothelial, Lung
Sources

Publications for Urethral Benign Neoplasm

About this section

Articles related to Urethral Benign Neoplasm:

# Title Authors Year
1
Case profile: prostatic adenoma masquerading as primary urethral neoplasm. ( 2459832 )
1988
Sources

Variations for Urethral Benign Neoplasm

About this section
Sources

Expression for Urethral Benign Neoplasm

About this section
Search GEO for disease gene expression data for Urethral Benign Neoplasm.
Sources

Pathways for Urethral Benign Neoplasm

About this section

Pathways related to Urethral Benign Neoplasm according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex 1
9.97 ATM SMAD4
Sources

GO Terms for Urethral Benign Neoplasm

About this section

Biological processes related to Urethral Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ovarian follicle development GO:0001541 9.16 ATM SMAD4
2 neuron apoptotic process GO:0051402 8.96 APP ATM
3 female gonad development GO:0008585 8.62 ATM SMAD4
Sources

Sources for Urethral Benign Neoplasm

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....